New Molecular Therapy Restores Insulation on Peripheral Nerves in Mice
This image from a paper in Nature Medicine shows how inhibiting an enzyme called HDAC3 in mice increases the expansion of Schwann cells (green). Schwann cells form a protective insulating layer called the myelin sheath around the nerves. Blocking HDAC3 increases the production of myelin proteins, shown in red.Credit: Cincinnati Children's Hospital Medical Center
When the body attacks its own healthy tissues in an autoimmune disease, peripheral nerve damage handicaps people and causes persistent neuropathic pain when insulation on healing nerves doesn't fully regenerate.
Unfortunately, there are no effective ways to treat the condition. Now scientists at Cincinnati Children's Hospital Medical Center describe in Nature Medicine an experimental molecular therapy that restores insulation on peripheral nerves in mice, improves limb function, and results in less observable discomfort.
Published Feb. 12, the study's principal investigator is Q. Richard Lu, PhD, director of the Cincinnati Children's Brain Tumor Center.
To identify possible therapies, the international team of investigators performed small-molecule epigenetic screening for compounds that inhibit enzymes involved in epigenetic changes on chromosomes. These changes alter how gene activity in cells is regulated. The authors identified small molecular inhibitors already used to treat certain cancers and tested them in experimental treatments on mice with injured sciatic nerves.
The molecular compounds target the enzyme HDAC3 (histone deacetylase 3). Study data show that HDAC3 inhibits regenerating insulation on recovering peripheral nerves.
"Remarkably, temporary inhibition of HDAC3 robustly accelerated the formation of myelin that helps insulate peripheral nerves," Lu says. "This promoted functional recovery in the animals after peripheral nerve injury."
Restoring Signal Relays
The peripheral nervous system relays signals from the brain and spinal cord (the central nervous system) to limbs and organs. HDAC3 is an enzyme found in humans and mice. Its usual job in peripheral nerve formation is to act as a molecular brake on the production of the myelin coating by Schwann cells.
After peripheral nerve injury, HDAC3 initiates epigenetic changes to chromosomes and gene regulation that excessively restrict myelin regeneration. This results in nerve insulation that is too thin or not totally formed, blocking or slowing signals between the spinal cord, extremities and organs.
Timing is Crucial
Researchers carefully timed their targeted treatments when inhibiting HDAC3, treating the mouse models of nerve injury only during a critical phase of nerve regeneration. This resulted in the right amount of re-myelination to restore normal function in the animals.
Getting the timing right on transient treatment is critical, Lu says. Researchers show that blocking HDAC3 for too long allows myelin to overgrow and cause excessively thick insulation. This also can lead to functional problems in extremities, according to study data.
From Science to Medicine
Translating data in the current study to clinical application in human patients will require extensive additional research, Lu says. Now that the prospective therapy has been successfully tested in mice, researchers are exploring additional research in animal models that more closely mimic the repair of injured peripheral nerves in people. This includes looking specifically at some demyelinating diseases that affect the central nervous system, such as multiple sclerosis.
Lu said this work will allow scientists to replicate and verify their findings in mice and other laboratory models. They also will be able to test possible dosing levels. If results are positive, Lu said researchers could pursue possible Phase I clinical trials in patients having deficient myelin in their peripheral and central nervous systems.
This article has been republished from materials provided by Cincinnati Children's Hospital Medical Center. Note: material may have been edited for length and content. For further information, please contact the cited source.
Researchers Democratize Neuroscience by Making it Easier to Share Brain Imaging DataNews
Researchers have developed a set of tools to make one critical area of big data research — that of our central nervous system — easier to share.READ MORE
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Neuroscientists Identify The Retrosplenial Cortex as an Integrator of Vision and Head MovementNews
Study highlights role of primary visual cortex in integrating head and visual movement signalsREAD MORE
Comments | 1 ADD COMMENT
Ashok Sewgobind | Feb 14, 2018
This is great news. As a AMN patient, im still waiting for the right cure or medicine. I hope this will do it.